- Potential benefitMay increase public awareness and fundraising for glioblastoma research and patient support.
- Potential benefitEncouraging biomarker testing could improve diagnostic precision and personalized treatment decisions.
- WorkersSupport for collaborative research and GTN could enhance coordination of trials and translational studies.
Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".
Referred to the House Committee on Energy and Commerce.
This resolution expresses the House of Representatives support for designating July 15, 2026 as "Glioblastoma Awareness Day" and encourages public awareness, honors patients and caregivers, and supports research efforts. It summarizes facts about glioblastoma and urges collaborative research and investment, including through the Glioblastoma Therapeutics Network. This is a statement of the House's position and does not create law or require action by other branches of government.
As a House simple resolution, it only requires approval by the House of Representatives; it does not go to the Senate or the President and is not legally binding.
This simple House resolution expresses support for designating July 15, 2026, as “Glioblastoma Awareness Day.” It notes glioblastoma incidence, poor survival, high patient costs, the importance of molecular biomarker testing, and encourages awareness, collaboration, and continued research, including support for the Glioblastoma Therapeutics Network.
This is a nonbinding House simple resolution that does not create law or require enactment; such measures do not become statutes.
Relative to its intended legislative type, this bill is an appropriately constructed commemorative resolution: it clearly defines the public health issue, designates a specific date, and enumerates non‑binding expressions and encouragements to raise awareness and support research.
Liberals emphasize linking awareness to funding and access
Who stands to gain, and who may push back.
These are examples from the analysis, not a ranked list of the most-affected groups.
- Potential burdenThe resolution is symbolic and creates no new funding, entitlements, or legal obligations.
- Potential burdenMay raise unrealistic expectations about near-term treatment advances without committing resources.
- Potential burdenGreater emphasis on biomarker testing could increase out-of-pocket expenses for some patients.
Why the argument around this bill splits.
Liberals emphasize linking awareness to funding and access
Likely strongly supportive as a compassionate, research-forward gesture that highlights patient burden and the need for improved treatments.
Would view it as a useful public-awareness tool but incomplete without commitments to funding and access.
Generally supportive as a noncontroversial, humanitarian recognition that promotes research collaboration.
Willing to back it while noting the resolution is symbolic and benefits would be greater with measurable follow-up actions.
Likely supportive in principle as a tribute to sufferers and families, but inclined to see it as symbolic federal action.
Prefers private charity, state-level efforts, and avoiding new federal spending or mandates.
The path through Congress.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
This is a nonbinding House simple resolution that does not create law or require enactment; such measures do not become statutes.
- Whether sponsors will seek a companion Senate resolution
- Whether text will be converted into a concurrent/public law measure
Recent votes on the bill.
No vote history yet
The bill has not accumulated any surfaced votes yet.
Go deeper than the headline read.
Liberals emphasize linking awareness to funding and access
This is a nonbinding House simple resolution that does not create law or require enactment; such measures do not become statutes.
Relative to its intended legislative type, this bill is an appropriately constructed commemorative resolution: it clearly defines the public health issue, designates a specific date, and enumerates non‑binding expressio…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.